Companies /Healthcare
Novartis AG ADR
NYSE: NVS Drug Manufacturers - General
$156.08
▼ $0.78 (−0.50%) today
Markets closed · 7:49pm ET

Novartis (NVS) Earnings History & Trends

EPS and revenue vs. Street estimates · SEC filings
75%
EPS beat rate
+4.41%
Avg. EPS surprise
Consecutive EPS beats
NVS vs Market · 30-day return after each reportNVSS&P 500
0%+4%+8%+6.8%−3.1%Q4 24+2.0%+6.3%Q1 25+8.3%+2.4%Q2 25+5.7%−0.5%Q3 25+6.5%−1.2%Q4 25+3.2%+6.3%Q1 26+1.5%+1.9%Q2 26
0%+4%+8%Q4 24Q2 25Q4 25Q2 26
NVS EPS Trend · estimate vs actualEstimateActual
$0.00$0.70$1.40$2.10$1.78$1.98Q4 24$2.17$2.28Q1 25$2.37$2.42Q2 25$2.31$2.25Q3 25$2.00$2.03Q4 25$2.07$1.99Q1 26$2.15$2.41Q2 26$2.24$2.46Q3 26
$0.00$0.70$1.40$2.10Q4 24Q2 25Q4 25Q2 26
NVS Revenue Trend · estimate vs actualEstimateActual
$0$5.0B$10.0B$15.0B$12.8B$13.2BQ4 24$13.0B$13.2BQ1 25$14.1B$14.1BQ2 25$13.8B$13.9BQ3 25$14.1B$13.3BQ4 25$13.5B$13.1BQ1 26$14.1B$14.4BQ2 26$14.6B$14.5BQ3 26
$0$5.0B$10.0B$15.0BQ4 24Q2 25Q4 25Q2 26

How Often Does Novartis Beat Earnings Estimates?

Novartis beat EPS estimates in 6 of its last 8 reported quarters, and has beaten 2 quarters in a row.

NVS quarterly earnings per share and revenue versus Street estimates
Quarter EPS · est. Surprise Revenue · est. Surprise
Q3 2026 Core EPS excludes Q3 core adjustments of USD 4,193 million. These include a USD 1.94 billion partial impairment of the del-desiran IPR&D asset and an onerous long-term supply contract provision of USD 0.6 billion. IFRS diluted EPS was USD 0.63. $2.46 est. $2.24 +9.74% $14.5B est. $14.6B −0.23%
Q2 2026 IFRS EPS of USD 1.71 was impacted by tax effects of an intercompany transaction and changes in uncertain tax positions, driving the tax rate to 23.7% vs 11.2% prior year. Excluding these, the tax rate would have been 17.3%. Restructuring expense was USD 472 million vs USD 147 million in Q2 2025. Intangible asset impairments were USD 199 million vs USD 92 million. $2.41 est. $2.15 +12.21% $14.4B est. $14.1B +2.50%
Q1 2026 $1.99 est. $2.07 −3.68% $13.1B est. $13.5B −2.72%
Q4 2025 $2.03 est. $2.00 +1.27% $13.3B est. $14.1B −5.26%
Q3 2025 $2.25 est. $2.31 −2.63% $13.9B est. $13.8B +0.45%
Q2 2025 $2.42 est. $2.37 +1.96% $14.1B est. $14.1B −0.20%
Q1 2025 $2.28 est. $2.17 +4.95% $13.2B est. $13.0B +1.40%
Q4 2024 $1.98 est. $1.78 +11.44% $13.2B est. $12.8B +2.57%

Figures from SEC filings and company reports. Not investment advice.